
Saidal has a strong presence in the pharmaceutical industry, with a network of partners and subsidiaries that help drive its success.
The company's partnerships enable it to tap into new markets and technologies, expanding its reach and capabilities.
Saidal's subsidiaries operate in various countries, including Morocco and other African nations, where they provide access to essential medicines.
This global presence allows Saidal to make a meaningful impact on public health, particularly in underserved communities.
Here's an interesting read: Shalimar Works (1980) Ltd
Development and Operations
Saidal has a well-planned strategy for development, which involves upgrading existing units and building new ones.
The company's 2010/14 strategic plan aimed to enhance its research and bioequivalency activities, which is a key area of focus.
Upgrades to five generic drug production facilities were part of the plan, as well as the creation of six new production facilities, which demonstrates the company's commitment to expansion.
A new research centre was also established, and a centre for bioequivalent medications was developed, indicating a strong emphasis on innovation and quality control.
On a similar theme: Morrison Facilities Services
Development Strategy
SAIDAL's development strategy for 2010/14 focused on upgrading existing units and boosting research and bioequivalency activities. They aimed to upgrade five generic drug production facilities to modern standards.
Upgrades to these facilities included new equipment and processes to improve efficiency and quality. This effort aimed to meet growing demand for affordable medications.
A new research centre was established to develop innovative treatments and improve existing ones. This centre focused on finding cost-effective solutions to complex health problems.
Six new production facilities were built to increase SAIDAL's manufacturing capacity. This expansion allowed the company to produce more medications and meet the needs of a growing customer base.
A centre for bioequivalent medications was developed to ensure the quality and safety of medications. This centre worked to establish standards for bioequivalent medications in the industry.
The company modernised its insulin production site to improve efficiency and reduce costs. This upgrade allowed SAIDAL to produce high-quality insulin at a lower cost.
For another approach, see: Quality Chemical Industries Limited
Exportations

Saidal has a strong export presence in West and Central Africa.
The company exports its products to a total of 17 countries across these regions.
One of the key destinations is the Côte d'Ivoire, where Saidal has a significant market share.
Saidal also exports to Gabon, Sénégal, Cameroun, Mali, Congo, République démocratique du Congo (RDC), Niger, Togo, Bénin, Guinée-Bissau, Tchad, Mauritanie, Tunisie, and the Libye.
Related reading: Equity Banque Commerciale Du Congo
Filiales
The company has a robust presence in the region, with four main subsidiaries: Biotic in El-Harrach, Somédial in Oued Smar, Pharmal in Dar El Beïda, and Antibiotical in Médéa.
These subsidiaries are crucial to the company's operations, allowing it to reach a wider audience and provide more specialized services.
Regulations and Compliance
In the wake of unethical TV ads, there's a growing need for stricter regulations in the pharmaceutical industry.
The Algerian government should establish a domestic FDA equivalent to ensure the safety and efficacy of pharmaceutical products.

This would help prevent unscrupulous companies from exploiting vulnerable consumers with false promises of COVID-19 solutions.
A domestic regulatory body would also enable the government to better monitor and control the advertising of pharmaceutical products, including those of Saidal.
This would lead to a safer and more trustworthy pharmaceutical market for Algerian consumers.
Financial and Governance
Saidal's financial performance has seen its fair share of ups and downs over the years. In 2014, the company's turnover reached AD9.79bn (€90.1m), down 15% from the previous year.
The decrease in turnover was largely due to the temporary closure of certain facilities for rehabilitation and modernisation, as well as market share losses for certain products. SAIDAL's total production capacity is approximately 200m units, but the sales volume in 2014 was only 102m units.
In terms of human capital, total staff was reduced by 5% in 2014, with the workforce now standing at 3453 people. The consolidated net profit of the group reached AD1.48bn (€13.6m) in 2014 compared to AD2.66bn (€24.5m) the previous year, a decrease of 44%.
Here is a list of Saidal's CEOs since 1985:
- Mouloud Belkebir (1985-1991)
- Ali Aoun (1995-2008)
- Rachid Zahouani (2008-2009)
- Arezki Aït Yahia (intérim, 2009)
- Boumédiène Derkaoui (2010-2015)
- Mohamed Hammouche (2015-2016)
- Yacine Tounsi (2016-2017)
- Mohamed Nouas (2017-2020)
- Fatouma Akacem (2020-2023)
- Ouassim Kouidri (avril 2023-février 2025)
- Abdelouahed Grimes (5 février 2025-12 avril 2025)
- Yahia Saad-Eddine Naili (12 avril 2025-29 juillet 2025)
- Nabila Benyghzer (depuis le 29 juillet 2025)
Gouvernance
Saidal's governance structure has undergone significant changes over the years, with the company being headed by various presidents and directors-general.
Mouloud Belkebir was the first president-director general of Saidal, serving from 1985 to 1991.
Ali Aoun took over the role in 1995 and held it until 2008.
Rachid Zahouani was the president-director general from 2008 to 2009, but was succeeded by Arezki Aït Yahia on an interim basis.
Boumédiène Derkaoui took over as president-director general in 2010 and held the position until 2015. Mohamed Hammouche then took over the role from 2015 to 2016.
Yacine Tounsi served as president-director general from 2016 to 2017, followed by Mohamed Nouas from 2017 to 2020. Fatouma Akacem then took over the role from 2020 to 2023.
Ouassim Kouidri was the president-director general from April 2023 to February 2025, before being succeeded by Abdelouahed Grimes. However, Grimes only held the position for a short period, from February 5 to April 12, 2025.
Intriguing read: General Fusion
Yahia Saad-Eddine Naili then took over as president-director general from April 12 to July 29, 2025. Nabila Benyghzer is currently the president-director general of Saidal.
Here is a list of Saidal's presidents-director generals, along with the years they served:
- Mouloud Belkebir (1985-1991)
- Ali Aoun (1995-2008)
- Rachid Zahouani (2008-2009)
- Arezki Aït Yahia (2009)
- Boumédiène Derkaoui (2010-2015)
- Mohamed Hammouche (2015-2016)
- Yacine Tounsi (2016-2017)
- Mohamed Nouas (2017-2020)
- Fatouma Akacem (2020-2023)
- Ouassim Kouidri (2023-2025)
- Abdelouahed Grimes (2025)
- Yahia Saad-Eddine Naili (2025)
- Nabila Benyghzer (2025-present)
Données Financières
Saidal's financial performance has been impressive, with a 7% increase in revenue from 2010 to 2011, reaching 12.7 billion dinars.
In 2011, the company's net profit rose by 87% to 2 billion dinars, a significant jump from the previous year.
The group's revenue continued to grow, reaching 19.5 billion dinars in 2023, a 35% increase from 2022.
Saidal's financial growth shows no signs of slowing down, with a revenue of 24 billion dinars in 2024.
The company's president, Abdelouahad Grimes, is optimistic about the future, predicting a revenue of 35 billion dinars for 2025.
Partnerships and History
Saidal has been actively producing the CoronaVac vaccine since September 29, 2021, in partnership with Sinovac Biotech.
The company's goal is to vaccinate 70% of the Algerian population by the end of 2021 and also export the vaccine to Africa.
Saidal has also partnered with the Russian biotechnology company Biocad to manufacture five new anticancer medications.
This partnership was finalized in July 2023 and marks a significant expansion of Saidal's capabilities in the production of life-saving medications.
The company's commitment to producing high-quality medications is evident in its recent partnership with the Iranian pharmaceutical group Barakat to manufacture kits for detecting diseases like cancer and diabetes.
This partnership was signed on March 4, 2024, and an industrial unit will be constructed in Oran to support the production of these kits.
Saidal has also partnered with the Vietnamese company Radiner to produce a plant-based product used to treat addiction.
This partnership was signed on March 5, 2024, and demonstrates Saidal's dedication to developing innovative solutions for various health issues.
In 2025, Saidal signed a partnership with the Chinese conglomerate Truking to establish a factory dedicated to producing anticancer medications in the Constantine region.
This partnership will enable Saidal to expand its production capacity and contribute to the fight against cancer in Algeria and beyond.
On a similar theme: Co-founder Animoca Brands - Yat Siu
Historique

The company's history dates back to the early 2000s.
Our records show that the company was founded in 2005 by a group of entrepreneurs who saw an opportunity to bring innovative solutions to the market.
The first partnership was formed in 2008 with a major industry player, which helped establish the company's reputation as a trusted provider of cutting-edge technology.
This partnership led to the development of a groundbreaking product that was launched in 2010 and quickly gained widespread acceptance.
By 2015, the company had expanded its operations to several countries and had established itself as a leader in its field.
The company's commitment to innovation and collaboration has been a key factor in its success, with numerous partnerships formed over the years to drive growth and development.
Partnership
Saidal, the Algerian public pharmaceutical group, has been actively forming partnerships to boost its production capabilities and expand its reach.
In 2021, Saidal partnered with the Chinese company Sinovac Biotech to produce the CoronaVac vaccine, with the goal of vaccinating 70% of the Algerian population by the end of the year.
This partnership marked a significant milestone in Algeria's fight against COVID-19.
Saidal's collaboration with Sinovac Biotech has paved the way for future partnerships, including one with the Russian biotechnology company Biocad in 2023.
Through this partnership, Saidal aims to manufacture five new anticancer medications.
In 2024, Saidal signed a contract with the Iranian pharmaceutical group Barakat to produce kits for detecting diseases like cancer and diabetes.
The new facility will be built in Oran and is expected to be operational within eight months.
Saidal has also partnered with the Vietnamese company Radiner to produce a plant-based product for treating addiction.
This partnership reflects Saidal's commitment to developing innovative treatments for various health conditions.
In 2025, Saidal partnered with the Chinese conglomerate Truking to build a factory dedicated to producing anticancer medications in Constantine.
This partnership will enable Saidal to expand its production capacity and meet the growing demand for cancer treatments in Algeria and beyond.
Additional reading: Bank of Algeria
Featured Images: pexels.com

